Search clinical trials for: Methylphenidate extended-release liquid formulation

Total 921 results

Massachusetts General Hospital

Completed

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

Autism Spectrum Disorder | Attention-deficit/Hyperactivity Disorder

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Novartis Pharmaceuticals

Completed

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder

Germany, United States, Belgium, Colombia, Denmark, Sweden
The University of Texas Health Science Center,...
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Autism | Attention Deficit Disorder With Hyperactivity

United States
UCB Pharma

Completed

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Epilepsy

Brazil, Finland, India, Mexico, Russian Federation, South Africa, Ukraine
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
Prof. Huss

Terminated

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA) (ASTA)

ADHD

Germany
Boston Children's Hospital
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

Epilepsy | Attention Deficit Disorder With Hyperactivity

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Purdue Pharma LP

Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (RE-DAX)

Attention-Deficit/Hyperactivity Disorder

United States
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
UCB Pharma

Completed

The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting

Attention Deficit Hyperactivity Disorder
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
Rhodes Pharmaceuticals, L.P.

Unknown

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD (EF004)

Attention Deficit Disorder With Hyperactivity

United States
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
Mahidol University

Not yet recruiting

The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original

Adhd
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Massachusetts General Hospital

Completed

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

Alzheimer Dementia

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Pfizer

Withdrawn

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

Attention Deficit Hyperactivity Disorder
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
Rhodes Pharmaceuticals, L.P.

Completed

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD (EF003)

Attention Deficit Disorder With Hyperactivity

United States
Center for Research and Production of Vaccines...
National Institute of Hygiene and Epidemiology, Vietnam; Children's Hospital... and other collaborators

Completed

Phase III Study of Liquid Formulation of ROTAVIN

Diarrhea | Diarrhea Rotavirus

Vietnam
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Rhodes Pharmaceuticals, L.P.

Completed

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

ADHD | Attention Deficit Hyperactivity Disorder

United States
Takeda

Completed

Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

Dengue Fever

United States
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Rhodes Pharmaceuticals, L.P.

Completed

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

ADHD | Attention Deficit Hyperactivity Disorder

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan

3

Subscribe